{"disease":{"id":"alport-syndrome","name":"alport syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04947813","title":"Genotype-Phenotype Correlations in Patients With Alport Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":8165,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT06526741","title":"ASF Alport Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Alport Syndrome Foundation","has_results":false},{"nct_id":"NCT05927467","title":"Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05133050","title":"Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":510,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04571658","title":"NEPTUNE Match Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":375,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT03749447","title":"An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":270,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06226896","title":"Effects of Dapagliflozin on Progression of Alport Syndrome","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":222,"lead_sponsor_name":"Nanjing University School of Medicine","has_results":false},{"nct_id":"NCT03019185","title":"A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT02136862","title":"ATHENA: Natural History of Disease Study in Alport Syndrome Patients","phase":"","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT04573920","title":"Atrasentan in Patients With Proteinuric Glomerular Diseases","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05655728","title":"Treatment With Metformin in Chinese Children With Alport Syndrome","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT05003986","title":"Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Travere Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07211685","title":"BAY3401016; Biomarker Study Alport","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04937907","title":"Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Shanghai Children's Hospital","has_results":false},{"nct_id":"NCT02855268","title":"Study of Lademirsen (SAR339375) in Patients With Alport Syndrome","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT05267262","title":"Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"River 3 Renal Corp.","has_results":false},{"nct_id":"NCT06731192","title":"Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT06499948","title":"Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Stefan Lujinschi","has_results":false},{"nct_id":"NCT06425055","title":"Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Enyo Pharma","has_results":false},{"nct_id":"NCT07523581","title":"EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Eloxx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06274489","title":"A Study to Evaluate Setanaxib in Patients With Alport Syndrome","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Calliditas Therapeutics AB","has_results":true},{"nct_id":"NCT03373786","title":"A Study of RG-012 in Subjects With Alport Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT05448755","title":"A Study of ELX-02 in Patients With Alport Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Eloxx Pharmaceuticals, Inc.","has_results":true}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}